Innovative Therapy Prapela specializes in noninvasive stimulation therapies that enhance breathing and oxygenation for newborns, presenting a unique offering in neonatal respiratory care which can be leveraged to expand into additional pediatric and neonatal health markets.

Regulatory Milestones Achieving Breakthrough Device Designation from the FDA positions Prapela as a pioneering company with validated technology, enabling easier access to hospital systems and accelerating adoption in clinical settings, which offers significant sales opportunities.

Funding & Recognition With over $8 million in awards and grants supporting clinical evaluation, Prapela demonstrates strong validation and credibility, making it an attractive partner for hospitals and healthcare providers looking for validated innovative solutions.

Market Expansion Prapela's recent release of the Prapela SVS baby box to soothe irritable newborns showcases product diversification, opening avenues to neonatal care product markets and opportunities to cross-sell to hospitals and neonatal units.

Growth Potential Despite current revenue below one million dollars, Prapela’s focused technological innovation, regulatory achievements, and funding support suggest significant growth potential, making it a compelling candidate for strategic partnerships and sales expansion within the neonatal medical device sector.